Genitourinary Cancers | Specialty

Immunotherapy Advances Again Propel Progress in GU Malignancies

August 11th 2016

Randy F. Sweis, MD, covers the immunotherapy advancements in prostate cancer, renal cell carcinoma, and bladder cancer, and what refinement lies ahead in each of these areas.

In Politics, Not Everybody Works Well Together

August 11th 2016

The lack of cooperation and inability to compromise, at the expense of our country’s best interests, has resulted in gridlock.

Dr. Michael L. Blute on Partial Nephrectomy Rates in RCC

August 10th 2016

Caring for US Veterans Helped Lead Iraqi Immigrant to Develop Prostate Cancer Advances

August 6th 2016

Maha H. Hussain, MB ChB, whose work has helped advance treatment and care of men with prostate cancer, was honored in the Genitourinary Cancer category with a 2015 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to recognize leaders in the field.

Dr. David F. McDermott on Nivolumab in RCC

August 5th 2016

New Checkpoint Target Emerges in Bladder Cancer

August 4th 2016

Alexander I. Sankin, MD, discusses how bladder cancer researchers are looking beyond PD-L1 and CTLA-4 to HHLA2, a potentially druggable new checkpoint target.

Dr. Peter O'Donnell on Atezolizumab and IMvigor 210

August 2nd 2016

With Its Long History and Pioneering Spirit, Urology of Virginia Faces a Changing Landscape

July 31st 2016

Michael Fabrizio, MD, and Dana Adams, COO, provide their perspective on the challenges that urology practices face today.

CHMP Grants Positive Opinion for Cabozantinib in Renal Cell Carcinoma

July 22nd 2016

Cabozantinib (Cabometyx) has received a positive recommendation from the EMA's Committee for Medicinal Products for Human Use for use as treatment for patients with advanced renal cell carcinoma after the failure of VEGF-targeted therapy.

CHMP Adopts Positive Opinion for Lenvatinib/Everolimus Combo in RCC

July 22nd 2016

The CHMP has recommended the approval of lenvatinib in combination with everolimus for patients with advanced renal cell carcinoma following one prior VEGF-targeted therapy.

Dr. Hristos Kaimakliotis on Predictive Markers in Bladder Cancer

July 22nd 2016

Dr. Haseebuddin on PD-1 Expression on Monocytes in RCC

July 21st 2016

Mohammed Haseebuddin, MD, a fellow in Urologic Oncology at Fox Chase Cancer Center, discusses the overall significance of a study examining an elevated preoperative classical monocyte PD-1 mean fluorescence intensity level in patients with clear cell renal cell carcinoma.

Dr. Randy Sweis on Impact of Atezolizumab Approval in Bladder Cancer

July 15th 2016

Expert Shares Potential of Durvalumab in Patients With Urothelial Bladder Cancer

July 15th 2016

Saeed Rafii, MD, PhD, MRCP, discusses the PD-L1 inhibitor durvalumab, the encouraging findings of it in Study 1108, and the evolving landscape of bladder cancer.

Dr. Pal on Biomarker Development in Renal Cell Carcinoma

July 15th 2016

Sumanta Kumar Pal, MD, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses biomarker development in the field of renal cell carcinoma (RCC).

Dr. Elizabeth Plimack on Nivolumab in Kidney Cancer

July 15th 2016

O'Donnell Discusses IMvigor Findings, Excitement Over Atezolizumab Approval in mUC

July 14th 2016

Peter O'Donnell, MD, discusses the encouraging IMvigor 210 results, the impact of atezolizumab (Tecentriq) in the treatment landscape, and the role of immunotherapy in metastatic urothelial carcinoma.

Dr. Rosenberg on Future Use of Atezolizumab in Bladder Cancer

July 13th 2016

Jonathan E. Rosenberg, MD, medical oncologist, Memorial Sloan Kettering Cancer, discusses ongoing research of and next steps with atezolizumab (Tecentriq) for the treatment of patients with metastatic urothelial carcinoma.

Dr. McDermott on Long-Term Benefit With Nivolumab in RCC

July 12th 2016

David F. McDermott, MD, associate professor of Medicine, Harvard Medical School, staff physician, director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses long-term follow-up results of treatment with nivolumab (Opdivo) for patients with renal cell carcinoma (RCC).

Adjuvant Sunitinib Improves DFS in Renal Cell Carcinoma

July 9th 2016

Sunitinib (Sutent) extended disease-free survival versus placebo as an adjuvant therapy for patients with renal cell carcinoma at high risk of recurrence in the phase III S-TRAC trial.